timothy sykes logo

Stock News

Globus Medical’s Strong Q3 Performance Sparks Investor Optimism

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Matt Monaco Fact-checked by Bryce Tuohey
Updated 11/7/2025, 11:33 am ET 11/7/2025, 11:33 am ET | 5 min 5 min read
Globus Medical’s Strong Q3 Performance Sparks Investor Optimism Thumbnail

Globus Medical Inc.’s stocks have been trading up by 32.39 percent due to positive market sentiment.

Candlestick Chart

Live Update At 11:32:49 EST: On Friday, November 07, 2025 Globus Medical Inc. stock [NYSE: GMED] is trending up by 32.39%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Overview

Globus Medical recently announced its Q3 financial performance, reporting non-GAAP earnings of $1.18 per share, a delightful escalation from $0.83 the previous year. The net sales surged to $769M, outperforming the anticipated $734.7M. Benefitting from this substantial growth, the company’s full-year adjusted EPS guidance has now been set between $3.75 and $3.85, defying prior projections of $3.21.

The stronger-than-forecasted figures are partly attributed to a 10% growth within the US Spine segment. Moreover, Globus Medical’s adept integration of the Nevro acquisition is another catalyst for these promising results. As the fiscal year 2025 shapes up, the revenue expectation has been refined from $2.8B-$2.9B to a more bullish $2.86B-$2.9B tranche. Glancing at the previous five-day trading range, GMED’s stock whooped from around $80 to a commendable close of $81.29, reflecting investor fervor.

Furthermore, the company’s balance sheet reveals a sound standing with low long-term debt and a favorable current ratio at 4.1. In terms of profitability, a robust gross margin of 62.8% supports the company’s growing revenue, indicative of its strong market footing.

Investor Confidence Soars

The recent financial disclosures and market reactions illustrate a revived investor optimism towards Globus Medical’s prospects. The notable beat on the earnings and revenue front during the Q3 report has injected a surge of confidence, not just among investors but also within the broader healthcare solutions market.

This positive sentiment is fanned by the clear demonstration of solid execution and strategic acquisitions that are contributing to top-line growth. Moreover, analysts have begun to reassess their financial expectations for GMED, as the successful integration of the Nevro business brings noticeable synergy benefits.

Market analysts continue to favor GMED with optimistic price targets. One key financial institution even revised its projections, hinting at a near-term upward trajectory as GMED showcases its strategic prowess in navigating competitive pressures within the medtech domain.

Moreover, the launch of the ANTHEM™ Elbow Fracture System, although earlier, continues to establish the company as a key player offering innovative solutions that support sustainable growth. This strategic roll-out aligns with Globus Medical’s ongoing investments in expanding its product portfolio and advancing its market competitiveness.

More Breaking News

Conclusion

As the fiscal year unfolds its dramatic financial narrative, Globus Medical’s performance and strategic initiatives back a landscape of optimism for stakeholders. The effective management of its core business alongside strategic expansions has underscored the organization’s reliability and long-term value creation potential.

In an environment driven by rapid technological advancements and competitive dynamics, Globus Medical appears to be navigating adeptly. Whether these tactical maneuvers translate into sustained stock performance remains to be seen, yet the current market smiles upon the strategic foresight and financial health presented by GMED. As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.” Traders, therefore, exercise patience, keenly observing forthcoming developments and relying on a robust trading strategy rather than impulsivity.

Certainly, stakeholders are keen to glean more about how Globus Medical will continue to unfold its robust blueprint for growth and innovation in the healthcare solutions sector.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”